FDA Classifies STI Detection Device for Quicker Patient Access
Published Date: 5/9/2025
Rule
Summary
The FDA is officially classifying a new device that detects germs causing sexually transmitted infections and their resistance markers as a Class II device with special safety rules. This change helps make sure the device is safe and works well, while also making it easier for patients to get access to these important tests. Companies making these devices will follow new guidelines starting now, which could speed up innovation without extra costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
STI Nucleic-Acid Tests Reclassified to Class II
The FDA is classifying devices that detect nucleic acids from non-viral germs causing sexually transmitted infections and their resistance markers as Class II (special controls). The agency says this classification provides reasonable assurance of safety and effectiveness and will enhance patients' access to these diagnostic tests.
New Special Controls for Device Makers
Manufacturers of the nucleic-acid STI and resistance-marker tests will be subject to special controls that are being codified as part of the device's Class II classification. The document says companies will follow these new guidelines starting now and that the action may reduce regulatory burdens and speed innovation.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in